SARS-CoV-2 spike RBD surface glycoprotein, Rabbit Polyclonal Antibody

As low as US$477.00
Only %1 left
Catalog Number
R-1963

    Product Info

  • Product Name SARS-CoV-2 spike RBD surface glycoprotein, Rabbit Polyclonal Antibody
  • Product Description google Rabbit anti-SARS-CoV-2 spike RBD surface glycoprotein Polyclonal Antibody (Unconjugated), suitable for ELISA, WB, ICC.
  • Alternative Names SARS-CoV-2 (COVID-19) Spike RBD Antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Surface Glycoprotein, Spike protein
  • Application(s) ELISA, ICC, WB
  • Antibody Host Rabbit
  • Antibody Type Polyclonal
  • Specificity Predicted reactivity based on immunogen sequence: SARS-CoV Spike proteins: (63%)
  • Species Reactivity Virus
  • Immunogen Description Anti-SARS-CoV-2 (COVID-19) Spike RBD antibody (R-1963-100) was raised against a peptide corresponding to 19 amino acids near the carboxy terminus of SARS-CoV-2 (COVID-19) Spike glycoprotein RBD.

    The immunogen is located within the last 50 amino acids of SARS-CoV-2 (COVID-19) Spike protein RBD.
  • Conjugate Unconjugated
  • Concentration 1 mg/mL
  • Purity Description Affinity-purified via peptide column.
  • Regulatory Status For research use only.

    Specifications

  • Product Description Rabbit anti-SARS-CoV-2 spike RBD surface glycoprotein Polyclonal Antibody (Unconjugated), suitable for ELISA, WB, ICC.
  • Application(s) ELISA, ICC, WB
  • Application Details WB: 2-5 μg/mL; ICC: 20 μg/mL.

    Antibody validated: Western Blot in human samples; Immunofluorescence in human samples. SARS-CoV-2 (COVID-19) Spike RBD Antibody can be used for the detection of SARS-CoV-2 (COVID-19) Spike protein in ELISA. It will detect 4 ng of free peptide at 1 μg/mL. All other applications and species not yet tested.
  • Target SARS-CoV-2 spike RBD surface glycoprotein
  • Specificity Predicted reactivity based on immunogen sequence: SARS-CoV Spike proteins: (63%)
  • Target Host Species Virus
  • Species Reactivity Virus
  • Antibody Host Rabbit
  • Antibody Type Polyclonal
  • Antibody Isotype IgG
  • Conjugate Unconjugated
  • Immunogen Description Anti-SARS-CoV-2 (COVID-19) Spike RBD antibody (R-1963-100) was raised against a peptide corresponding to 19 amino acids near the carboxy terminus of SARS-CoV-2 (COVID-19) Spike glycoprotein RBD.

    The immunogen is located within the last 50 amino acids of SARS-CoV-2 (COVID-19) Spike protein RBD.
  • Homology Predicted reactivity based on immunogen sequence: SARS-CoV Spike proteins: (63%)
  • Isoform Information SARS-CoV-2 (COVID-19) Spike has one isoform (1273aa).
  • Purity Description Affinity-purified via peptide column.
  • Format Liquid. SARS-CoV-2 (COVID-19) Spike RBD antibody is supplied in PBS containing 0.02% sodium azide. Conc.1 mg/mL
  • Concentration 1 mg/mL
  • Reconstitution Instructions Spin vial briefly before opening.
  • Storage Instructions SARS-CoV-2 (COVID-19) Spike RBD antibody can be stored at 2-8°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
  • Batch Number Please see item label.
  • Expiration Date 12 months after date of receipt (unopened vial).
  • Alternative Names SARS-CoV-2 (COVID-19) Spike RBD Antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Surface Glycoprotein, Spike protein
  • Uniprot Number P0DTC2
  • Uniprot Number/Name P0DTC2 (SPIKE_SARS2)
  • NCBI Official Full Name surface glycoprotein
  • NCBI Official Symbol S
  • NCBI Organism SARS-CoV-2
  • Scientific Background Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).
  • Research Area Infectious Disease
  • Shipping Temperature 2-8°C (on cold packs)
  • UNSPSC CODE 41116161
  • Regulatory Status For research use only.

    Images, Protocols & SDS

  • Figure 1 Western Blot Validation with SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein
    Loading: 30 ng per lane of SARS-CoV-2 (COVID-19) Spike RBD recombinant protein, 10-303. Antibodies: SARS-CoV-2 (COVID-19) Spike RBD, R-1963-100, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 1 µg/mL and Lane 2: 2 µg/mL.

  • Figure 2 ELISA Validation with SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein
    Antibodies: SARS-CoV-2 (COVID-19) Spike RBD antibody, R-1963-100 (1 μg/mL). A direct ELISA was performed using SARS-CoV-2 (COVID-19) Spike RBD recombinant protein (10-303) as coating antigen and the anti-SARS-CoV-2 (COVID-19) Spike RBD antibody as the capture


    Figure 3 Immunofluorescence Validation of SARS-CoV-2 (COVID-19) Spike RBD in 293 Transfected Cells
    Immunofluorescent analysis of 4% paraformaldehyde-fixed Spike transfected 293 cells labeling SARS-CoV-2 (COVID-19) Spike RBD with R-1963-100 at 20 mg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).


    Figure 4 Overexpression Validation in Spike Transfected 293 Cells
    Loading: 10 μg per lane of 293 cell lysate. Antibodies: SARS-CoV-2 (COVID-19) Spike RBD, R-1963-100 (4 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: WT 293 cells and Lane 2: SARS-CoV-2 Spike overexpressed 293 cells


    Figure 5 Western Blot Validation with SARS-CoV-2 (COVID-19) Spike RBD+SD1 Recombinant Protein
    Loading: 30 ng per lane of SARS-CoV-2 (COVID-19) Spike RBD+SD1 recombinant protein, 10-304. Antibodies: SARS-CoV-2 (COVID-19) Spike RBD, R-1963-100, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 1 µg/mL and Lane 2: 2 µg/mL.


    Figure 6 ELISA Validation with SARS-CoV-2 (COVID-19) Spike RBD+SD1 Recombinant Protein
    Antibodies: SARS-CoV-2 (COVID-19) Spike RBD antibody, R-1963-100 (1 μg/mL). A direct ELISA was performed using SARS-CoV-2 (COVID-19) Spike RBD+SD1 recombinant protein (10-304) as coating antigen and the anti-SARS-CoV-2 (COVID-19) Spike RBD antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 8 ng/mL to 1000ng/mL.


    Figure 7 Western Blot Validation with SARS-CoV-2 (COVID-19) Spike RBD+SD1+SD2 Recombinant Protein
    Loading: 30 ng per lane of SARS-CoV-2 (COVID-19) Spike RBD+SD1+SD2 recombinant protein, 10-305. Antibodies: SARS-CoV-2 (COVID-19) Spike RBD, R-1963-100, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 1 µg/mL and Lane 2: 2 µg/mL.

    Citations & References

  • General References Gorbalenya. bioRxiv: 2020.
    Hui et al. Int J Infect Dis. 2020;91:264-266.
    Belouzard et al. Viruses. 2012;4(6):1011-33.
    Lee et al. J Virol. 2006;80(8):4079-87.
    Wan et al. J Virol. 2020.
    Wrapp et al. Science. 2020.